Abstract | BACKGROUND: METHODS: RESULTS: Forty-four patients (median age, 74 yr) were analyzed. The majority (N=42, 95.5%) had advanced stage disease and 36 (81.8%) were classified as high/high-intermediate risk by the international prognostic index. The overall response rate was 61.4%, and 21 patients achieved complete response (47.7%). With median follow-up period of 28.8 months, the estimated two-year progression-free and overall survival rates were 36.7% and 46.6%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 26.9% and 7.4% of 204 total cycles, which affected 76.7% and 25.6% of the patients, respectively. Nineteen patients (44.2%) experienced febrile neutropenia, and six died due to treatment-related toxicities. High lactate dehydrogenase levels and an involvement of >1 extranodal sites were prognostic indicators of poor survival. CONCLUSION: Dose-attenuated CHOP does not compromise treatment efficacy but retains significant toxicity. Our results suggest that some patients can be effectively treated with dose-attenuated CHOP, however a novel therapy for elderly patients with PTCL is required.
|
Authors | Eun-Ji Choi, Jung Yong Hong, Dok Hyun Yoon, Jihoon Kang, Chan-Sik Park, Jooryung Huh, Eun Jin Chae, Yoonse Lee, Jin-Sook Ryu, Cheolwon Suh |
Journal | Blood research
(Blood Res)
Vol. 52
Issue 4
Pg. 270-275
(Dec 2017)
ISSN: 2287-979X [Print] Korea (South) |
PMID | 29333403
(Publication Type: Journal Article)
|